Navigation Links
Regeneron Announces September 2012 Investor Conference Presentations
Date:8/29/2012

TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Robert W. Baird Healthcare Conference at 1:20 p.m. Eastern Time on Wednesday, September 5, 2012
  • Morgan Stanley Global Healthcare Conference at 3:55 p.m. Eastern Time on Tuesday, September 11, 2012
  • UBS Global Life Sciences Conference at 7:30 a.m. Eastern Time on Thursday, September 20, 2012
  • The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page.  Archived versions of the presentations will be available for thirty days after the live webcasts. 

    Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use.  Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.

    Peter DworkinInvestor Relations

    Corporate Communications914-847-5126

    914.847.764manisha.narasimhan@regeneron.com 

    peter.dworkin@regeneron.com


    '/>"/>
    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
    2. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
    3. Regeneron Announces June 2012 Investor Conference Presentations
    4. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
    5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
    6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
    7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
    8. Misonix Announces New Distribution Agreement For Panama
    9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
    10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/17/2017)... 2017  Market Research Future published a Half Cooked Research Report ... to reach USD 33.6 million during the period 2016 to 2022 ... ... Market has been examined as a swiftly growing market and expected ... for endoscopy device in various regions.  The increasing growth in endoscopy ...
    (Date:1/17/2017)... Research and Markets has announced the addition of the ... their offering. ... The global fluoropolymer market in the healthcare industry to grow at ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, has been prepared ... The report covers the market landscape and its growth prospects over ...
    (Date:1/17/2017)... , Jan. 17, 2017   Tocagen Inc ., a ... , Ph.D., executive vice president, research and pharmaceutical development at Tocagen, ... , to be held Jan. 17-20 in Miami ... follows: ... biotech oxymoron: exciting manufacturing for replicating viruses - what to do ...
    Breaking Medicine Technology:
    (Date:1/17/2017)... ... ... Stalking Awareness Month (NSAM), now in its fourteenth year, when we turn the spotlight ... a very real danger to many in our community. We also take a look ... “Stalking: know it. Name it. Stop it.”—so reads the theme for this importance observance. ...
    (Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... concerned by the political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting interview with ... magical moments that help everyone endure and pass through tough times, Dr. Bernie ...
    (Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
    (Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s fastest ... practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of the ... to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD and ...
    (Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, tax, ... in its IT Advisory Services practice . Rossi is the third technology consulting ... for strategic IT guidance grows, and the practice continues to expand.     , Bringing more ...
    Breaking Medicine News(10 mins):